ProteoMediX has developed Proclarix, a next-generation blood test designed to enhance the diagnosis of prostate cancer, particularly for patients with elevated PSA levels. This non-invasive test utilizes the same blood sample as traditional PSA testing, providing a rapid and precise assessment without the need for invasive tissue biopsies. Proclarix is particularly beneficial for patients whose PSA levels fall within the diagnostic grey zone (2 to 10 ng/ml), where traditional methods may lead to inconclusive results and unnecessary anxiety. By delivering clear diagnostic support through the Proclarix Risk Score, the test helps physicians make informed decisions regarding further medical investigation, thereby improving patient management and satisfaction.

The underlying technology of Proclarix is rooted in advanced proteomics and immunoassay techniques, which were developed through research at the Swiss Federal Institute of Technology in Zurich. The test measures specific cancer-related proteins, including thrombospondin 1 and cathepsin D, using quantitative Enzyme-Linked Immunosorbent Assays (ELISA). By integrating these biomarker values with patient age and PSA levels, Proclarix generates a comprehensive risk score that aids in identifying patients at risk for high-grade prostate cancer. This innovative approach not only reduces the number of unnecessary biopsies but also enhances the overall efficiency of prostate cancer diagnosis, ultimately benefiting both patients and the healthcare system.

Switzerland

Proteomedix enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies.

The first product is a blood-based test for the early diagnosis of prostate cancer. The main benefit of this test is a significantly higher accuracy compared to today's clinical standard (blood-based PSA test). This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.

ProteoMediX

Company Details